Latest articles from MPR http://feeds2.feedburner.com/mprhome Latest articles from MPR Home Home custserv@haymarketmedia.com no Nuzyra Now Available in IV, Oral Forms for CABP, ABSSSI Nuzyra, an aminomethylcycline (related to tetracycline antibiotics), is designed to overcome tetracycline resistance and has broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, and other drug-resistant strains. https://www.empr.com/nuzyra-omadacycline-intravenous-tablet-for-pneumonia-skin-infections-available/article/832278/ Wed, 06 Feb 2019 14:00:00 GMT Nuzyra, an aminomethylcycline (related to tetracycline antibiotics), is designed to overcome tetracycline resistance and has broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, and other drug-resistant strains. https://www.empr.com/nuzyra-omadacycline-intravenous-tablet-for-pneumonia-skin-infections-available/article/832278/ Pexidartinib Gets Priority Review for Tenosynovial Giant Cell Tumor The NDA is supported by data from the Phase 3 ENLIVEN study (N=120) which randomized patients with symptomatic TGCT to receive pexidartinib or placebo to evaluate the safety and efficacy of the treatment. https://www.empr.com/pexidartinib-new-drug-application-accepted-for-tenosynovial-giant-cell-tumors/article/832070/ Wed, 06 Feb 2019 13:00:00 GMT The NDA is supported by data from the Phase 3 ENLIVEN study (N=120) which randomized patients with symptomatic TGCT to receive pexidartinib or placebo to evaluate the safety and efficacy of the treatment. https://www.empr.com/pexidartinib-new-drug-application-accepted-for-tenosynovial-giant-cell-tumors/article/832070/ Alyq, a Generic Version of PAH Treatment Adcirca, Now Available Alyq should not be used with concomitant organic nitrates or guanylate cyclase (GC) stimulators (eg, riociguat), and in patients with a known serious hypersensitivity to tadalafil. https://www.empr.com/teva-alyq-tablets-generic-adcirca-for-pulmonary-arterial-hypertension-available/article/832360/ Wed, 06 Feb 2019 12:30:00 GMT Alyq should not be used with concomitant organic nitrates or guanylate cyclase (GC) stimulators (eg, riociguat), and in patients with a known serious hypersensitivity to tadalafil. https://www.empr.com/teva-alyq-tablets-generic-adcirca-for-pulmonary-arterial-hypertension-available/article/832360/ Compounded Pain Creams Evaluated in Patients With Localized Chronic Pain To investigate the effectiveness of compounded creams in the treatment of chronic pain conditions, study authors performed a double-blind, randomized, parallel study comparing creams compounded with an active ingredient to placebo creams. https://www.empr.com/compounded-topical-pain-creams-for-chronic-pain-efficacy-evaluated/article/832051/ Tue, 05 Feb 2019 19:00:00 GMT To investigate the effectiveness of compounded creams in the treatment of chronic pain conditions, study authors performed a double-blind, randomized, parallel study comparing creams compounded with an active ingredient to placebo creams. https://www.empr.com/compounded-topical-pain-creams-for-chronic-pain-efficacy-evaluated/article/832051/ Clinician Sued for Wrongful Death After Overlooking Drug Allergy in Medical Record The patient had a history of asthma, COPD, diabetes and severe anaphylactic reactions to multiple medicines. https://www.empr.com/missed-antibiotic-allergy-wrongful-death-lawsuit/article/831951/ Tue, 05 Feb 2019 18:00:00 GMT The patient had a history of asthma, COPD, diabetes and severe anaphylactic reactions to multiple medicines. https://www.empr.com/missed-antibiotic-allergy-wrongful-death-lawsuit/article/831951/ ACIP Updates Recommendations for US Adult Immunization Schedule The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US. https://www.empr.com/american-committee-on-immunization-practices-and-cdc-issue-vaccine-updates/article/832259/ Tue, 05 Feb 2019 17:00:00 GMT The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US. https://www.empr.com/american-committee-on-immunization-practices-and-cdc-issue-vaccine-updates/article/832259/ FDA to Review Two Antibacterial Agents for Potentially Life-Threatening Infections Both filings have been granted Priority Review by the Agency. https://www.empr.com/merck-antibacterial-drugs-nda-review-relebactam-urinary-abdominal-infections/article/832056/ Tue, 05 Feb 2019 17:00:00 GMT Both filings have been granted Priority Review by the Agency. https://www.empr.com/merck-antibacterial-drugs-nda-review-relebactam-urinary-abdominal-infections/article/832056/ Novel Glioblastoma Treatment Granted Orphan Drug Designation In preclinical models, the inhibition of phosphorylated STAT3 (p-STAT3) by WP1066 resulted in the direct attack of various tumor cells. https://www.empr.com/glioblastoma-treatment-wp1066-orphan-drug-designation/article/832054/ Tue, 05 Feb 2019 14:56:33 GMT In preclinical models, the inhibition of phosphorylated STAT3 (p-STAT3) by WP1066 resulted in the direct attack of various tumor cells. https://www.empr.com/glioblastoma-treatment-wp1066-orphan-drug-designation/article/832054/ FDA to Review Cenobamate for the Treatment of Partial-Onset Seizures While the exact mechanism of action of cenobamate is not fully understood, it is believed to work through a dual mechanism. https://www.empr.com/new-drug-application-accepted-for-antiepileptic-treatment-cenobamate/article/831752/ Mon, 04 Feb 2019 19:00:00 GMT While the exact mechanism of action of cenobamate is not fully understood, it is believed to work through a dual mechanism. https://www.empr.com/new-drug-application-accepted-for-antiepileptic-treatment-cenobamate/article/831752/ Yutiq Now Available for Chronic Non-Infectious Posterior Segment Uveitis It is designed to release fluocinolone acetonide, a corticosteroid, at an initial rate of 0.25mcg/day. https://www.empr.com/yutiq-fluocinolone-acetonide-intravitreal-implant-for-uveitis-available/article/831746/ Mon, 04 Feb 2019 16:30:00 GMT It is designed to release fluocinolone acetonide, a corticosteroid, at an initial rate of 0.25mcg/day. https://www.empr.com/yutiq-fluocinolone-acetonide-intravitreal-implant-for-uveitis-available/article/831746/